摘要
目的研究乳腺癌耐药蛋白(BCRP)与细胞核相关抗原(ki67)在乳腺癌组织的表达及其与临床病理特征的关系.方法以2008年3月~2013年3月海南省妇幼保健院收治的乳腺癌患者60例为观察对象,分别采集所有患者乳腺癌组织与癌旁正常组织.以免疫组化法分别检测不同组织中BCRP与ki67的表达情况,并分析乳腺癌组织中BCRP、ki67表达情况与患者临床病理特征的关系.所有患者均进行为期5年的随访,将患者是否复发分为复发组与未复发组,比较两组BCRP与ki67表达情况.结果乳腺癌组织中BCRP、ki67阳性率分别为43.33%、75.00%,高于癌旁正常组织的16.67%、28.33%,差异均有统计学意义(P<0.05).TNM分期为Ⅲ~Ⅳ期乳腺癌患者组织中BCRP阳性率高于TNM分期为Ⅰ~Ⅱ期患者、有淋巴结转移乳腺癌患者组织中BCRP阳性率高于无淋巴结转移患者,差异均有统计学意义(P<0.05).TNM分期为Ⅲ~Ⅳ期乳腺癌患者组织中ki67阳性率高于TNM分期为Ⅰ~Ⅱ期患者、有淋巴结转移乳腺癌患者组织中ki67阳性率高于无淋巴结转移患者,差异有统计学意义(P<0.05).乳腺癌5年复发组患者BCRP、ki67阳性率分别为62.07%、93.10%,高于未复发组的25.81%、58.06%,差异均有统计学意义(P<0.05).结论乳腺癌患者BCRP与ki67均存在明显高表达,且两者均与乳腺癌临床分期、淋巴结转移密切相关,对BCRP与ki67表达进行检测有助于乳腺癌的早期诊断、病情判断及预后评估.
Objective To study the expression of breast cancer drug resistant protein( BCRP) and ki67 in breast cancer tissues and analyze its relationship with pathological features. Methods A total of 60 cases of breast cancer patients admitted to our hospital from March 2008 to March 2013 were studied, and all breast cancer tissues and adjacent normal tissues were collected. The expression of BCRP and ki67 in different tissues was detected by immunohistochemistry, and the relationship between the expression of BCRP and ki67 in breast cancer tissues and the clinical and pathological features of patients was analyzed. In addition, all the patients were followed up for 5 years, and the patients were divided into the recurrence group and the non-recurrence group, and the expression of BCRP and ki67 in the two groups were compared. Results The positive rates of BCRP and ki67 in breast cancer tissues were 43.33% and 75.00%, respectively, which were higher than those in adjacent normal tissues, The positive rates were 16.67% and 28.33%. The difference was statistically significant(P < 0.05). The positive rate of BCRP in patients with stage Ⅲ~Ⅳ breast cancer was higher than that in patients with stage Ⅲ~Ⅳ breast cancer. The positive rate of BCRP in patients with lymph node metastasis was higher than that in patients without lymph node metastasis. The differences were statistically significant(P < 0.05). The positive rate of ki67 in patients with stage Ⅲ~Ⅳ breast cancer was higher than that in patients with stage Ⅲ~Ⅳ breast cancer, and the positive rate of ki67 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis. The differences were statistically significant(P < 0.05). The positive rates of BCRP and ki67 in the 5-year recurrence group were 62.07% and 93.10%, respectively, which were higher than those in the non-recurrent group(25.81%, 58.06%). The differences were statistically significant(P < 0.05). Conclusion Both BCRP and ki67 are significantly highly expressed in breast cancer patients, and both are closely related to clinical stage and lymph node metastasis of breast cancer. The expression of BCRP and ki67 can be detected in clinical work, which is helpful for the early diagnosis, disease judgment and prognosis evaluation of breast cancer.
作者
周蓓
王婧
吴忠
ZHOU Pei;WANG Jing;WU Zhong(Department of Clinical Medicine, South China University of Medicine, Hengyang Hunan 421001;Department of breast surgery,Hainan maternal and child health care hospital, Haikou Hainan 570206, China)
出处
《中国处方药》
2019年第8期12-14,共3页
Journal of China Prescription Drug
关键词
乳腺癌
乳腺癌耐药蛋白
KI67
临床病理特征
Breast cancer
Breast cancer drug resistant protein
Ki67
Clinical pathologic features
